4-甲氧基-4-甲基环己烷-1-醇 | 143734-15-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-甲氧基-4-甲基环己烷-1-醇
• 英文名称: 4-methoxy-4-methylcyclohexan-1-ol
• CAS: 143734-15-0；143734-16-1
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: UQLJIQBFAPIEJT-UHFFFAOYSA-N

物化性质

• 沸点：
  213.3±8.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  甲醇 、 对甲苯甲醚 生成 4-甲基环己醇 、 4-甲氧基-4-甲基环己烷-1-醇 、 trans-4-methoxy-4-methylcyclohexan-1-ol
  参考文献：
  名称：

  Reaction of azoalkanes with isolable cation radical salts

  摘要：

  Three tertiary azoalkanes related in the sense acyclic, cyclic, and bicyclic are shown to evolve nitrogen upon oxidation with stable cation radical salts. Thus azo-tert-octane (ATO), 3,3,6,6-tetramethyl-1,2-diazacyclohexene (TMDAC), and 1,4-dimethyl-2,3-diazabicyclo[2.2.2]oct-2-ene (Me2DBO) react rapidly with thianthrenium perchlorate (Th.+ClO4-), tris(p-bromophenyl)aminium hexachloroantimonate (TBPA.+SbCl6-), and TBPA.+SbF6-. The ether and olefin products, which are formed in high yield in CH2Cl2/MeOH solvent, are not those expected from the usual free-radical decomposition of azoalkanes but instead implicate carbocations. Although the reaction stoichiometry clearly requires 2 equiv of cation radical salt to one of azoalkane, the mechanism is not yet clearly defined. A complication in these studies is found in the ability of certain cation radical salts to oxidize more azoalkane than expected based on the 2:1 stoichiometry.

  DOI：

  10.1021/jo00049a025

文献信息

• [EN] COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS<br/>[FR] COMPOSÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013027001A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6, X1, X2, X3, X4, A1 and L1, are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（1）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、m、n、p、q、Q1、Q2、Q3、Q4、Q5、Q6、X1、X2、X3、X4、A1和L1如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• [EN] INHIBITORS OF RET<br/>[FR] INHIBITEURS DE RET
  申请人：BLUEPRINT MEDICINES CORP

  公开号：WO2017079140A1

  公开（公告）日：2017-05-11

  Inhibitors of wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

  抑制野生型RET及其耐荐抗性突变体的抑制剂，包括这些化合物的药物组合物，以及使用这些化合物和组合物的方法。
• INHIBITORS OF RET
  申请人：Blueprint Medicines Corporation

  公开号：EP3371171A1

  公开（公告）日：2018-09-12
• [EN] HETEROCYCLES AND USES THEREOF<br/>[FR] HÉTÉROCYCLES ET LEURS UTILISATIONS
  申请人：[en]KUMQUAT BIOSCIENCES INC.

  公开号：WO2022081912A2

  公开（公告）日：2022-04-21

  The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
• WO2022271562A1
  申请人：——

  公开号：WO2022271562A1

  公开（公告）日：2022-12-29